DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Pierre - 2 Alain Ruffieux - 2 Albert Baehny - 2 Denis Balibouse - 1 Aimee Donnellan - 1 Neil Unmack - 1 Streisand Neto - 1 Arnd - 1
Top related locs:
Lonza Switzerland Swiss Visp Basel Zurich Frankfurt
Top related orgs:
REUTERS - 2 Thomson - 2 Swiss - 1 X - 1 Monday - 1 Ruffieux - 1 Roche - 1 Lonza - 1

Search resuls for: "Alain Ruffieux"


3 mentions found


☆ Lonza’s CEO churn adds to company’s ailments
  + stars: | 2023-09-18 | by ( ) www.reuters.com   time to read: +2 min
REUTERS/Denis Balibouse Acquire Licensing RightsLONDON, Sept 18 (Reuters Breakingviews) - Lonza’s (LONN.S) new broom will face even more challenges than its old one. Since he was appointed CEO in 2020, the Swiss group has increased capital expenditure as a percentage of revenue from 20% to 30% last year. Even before Monday’s fall, the stock was trading at 32 times its forward earnings, around the same level as before its pandemic surge. The disruption of another CEO exit, without a clear explanation, means that the hoped-for growth will take even longer to arrive. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.
Persons: Denis Balibouse, Pierre, Alain Ruffieux, Albert Baehny, Aimee Donnellan, Neil Unmack, Streisand Neto Organizations: REUTERS, Reuters, Swiss, X, Thomson Locations: Lonza, Visp, Switzerland, Swiss
☆ Lonza CEO departure prompts concern over earnings prospects
  + stars: | 2023-09-18 | by ( Ludwig Burger Noele Illien | Ludwig Burger | Noele Illien | ) www.reuters.com   time to read: +2 min
The logo of Swiss contract drug maker Lonza is seen at its headquarters in Basel, Switzerland October 1, 2020. Shares in Lonza, which makes drug ingredients for healthcare and biotech companies, dropped 5.3% shortly after the 0700 GMT market open, trading near an eight-month low. A former Roche executive who joined Lonza in 2020, Ruffieux oversaw the company's role in producing COVID-19 vaccines for Moderna (MRNA.O) during the pandemic. "Today’s announcement increases our conviction that the new mid-term targets will not include an acceleration in growth," they said. Lonza did not provide a reason for Ruffieux's departure.
Persons: Arnd, Pierre, Alain Ruffieux, Lonza, Albert Baehny, Ruffieux, Morgan, Spokespeople, Merck KGaA, Noele, Ludwig Burger, Rachel More, David Goodman, Emelia Organizations: REUTERS, Monday, Ruffieux, Roche, Lonza, Moderna, Merck, Noele Illien, Thomson Locations: Basel, Switzerland, Swiss, Lonza, Zurich, Frankfurt
☆ Lonza to buy back $2.17 bln worth of shares, backs mid-term growth
  + stars: | 2023-01-25 | by ( Ludwig Burger Tristan Chabba | Ludwig Burger | Tristan Chabba | ) www.reuters.com   time to read: +2 min
[1/2] A logo is pictured on the Ibex building of Lonza, where the Moderna mRNA coronavirus disease (COVID-19) vaccine will be produced, in Visp, Switzerland, September 29, 2020. REUTERS/Denis Balibouse/File PhotoJan 25 (Reuters) - Lonza (LONN.S) on Wednesday said it will buy back shares worth 2 billion Swiss francs ($2.17 billion), despite an expected drop in annual margins, as the Swiss drug contract manufacturer backed its growth prospects for the near future. Lonza expects its 2023 core earnings before interest, depreciation and amortization, or EBITDA margin, to slip between 30% and 31%, down from 32.1% in 2022, as last year's boost from COVID-19 vaccine manufacturing services waned. The Basel-based company, however, reiterated a target of 33%-35% for 2024 marginsand announced a 17% rise in its annual dividend. The Swiss group forecast sales growth in the "high single-digit" adjusted for currency swings, a slow-down from the 15.1% rise it saw last year.
0 next >>
Total: 3